Markets:

Overview

News

Currencies

International

Treasuries

Arcturus Therapeutics Holdings Inc (NQ:ARCT)

6.750 -0.280 (-3.98%)

Streaming Delayed Price Updated: 12:45 PM EDT, May 19, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Arcturus Therapeutics Holdings Inc

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Mid-Day Market Update: Crude Oil Down 2%; Arcturus Therapeutics Shares Spike Higher ↗

August 03, 2021

Midway through trading Tuesday, the Dow traded up 0.11% to 34,878.06 while the NASDAQ fell 0.37% to 14,626.97. The S&P also fell, dropping 0.01% to 4,386.68. The U.S. has the...

Via Benzinga

Topics Stocks

48 Stocks Moving In Tuesday's Mid-Day Session ↗

August 03, 2021

Gainers Wilhelmina International, Inc. (NASDAQ: WHLM) shares jumped 64.4% to $7.15 after a Form 4 filing from the company showed 10% shareholder Retail Ecommerce Ventures...

Via Benzinga

Why Arcturus Therapeutics Stock Is Soaring Today ↗

August 03, 2021

The company received a green light to advance two COVID-19 vaccine candidates into clinical testing in a second country.

Via The Motley Fool

The Daily Biotech Pulse: Sanofi Buys Translate Bio In $3.2B Deal, Lilly's Q2 Earnings Disappoint, Bausch To Spin Off Medical Aesthetics Business ↗

August 03, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 2) Absci, CORP (NASDAQ: ABSI) (...

Via Benzinga

21 Stocks Moving in Tuesday's Pre-Market Session ↗

August 03, 2021

Gainers Wilhelmina International, Inc. (NASDAQ: WHLM) shares rose 46% to $6.35 in pre-market trading following Form 4 filing from the company’s 10% owner, Retail Ecommerce...

Via Benzinga

Arcturus Announces Approval of Singapore Clinical Trial Application to Advance ARCT-154 and ARCT-165, Next Generation STARR™ mRNA Vaccines Targeting SARS-CoV-2 Variants of Concern, in a Phase 1/2 Study

August 03, 2021

From Arcturus Therapeutics Holdings Inc.

Via Business Wire

10 Health Care Stocks Showing Unusual Options Activity In Today's Session ↗

August 02, 2021

This unusual options alert can help traders discover the next big trading opportunities. Traders will search for circumstances when the market estimation of an option diverges...

Via Benzinga

Arcturus' COVID-19 mRNA Vaccine Candidate To Target Variants, Trial To Start In Vietnam ↗

August 02, 2021

The Vietnam Ministry of Health has signed off Arcturus Therapeutics Holdings Inc's (NASDAQ: ARCT) Clinical Trial Application (CTA) to advance ARCT-154 COVID19...

Via Benzinga

Arcturus Therapeutics Stock Jumps On Establishment Of COVID-19 Vaccine Plant In Vietnam ↗

August 02, 2021

Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) has collaborated with Vinbiocare to establish a manufacturing facility in Vietnam for its...

Via Benzinga

Arcturus Announces Approval of a Clinical Trial Application to Advance ARCT-154, a Next Generation STARR™ mRNA Vaccine Targeting the SARS-CoV-2 Delta Variant and Other Variants of Concern

August 02, 2021

From Arcturus Therapeutics Holdings Inc.

Via Business Wire

Arcturus Therapeutics Collaborates with Vingroup to Establish Manufacturing Facility in Vietnam for Arcturus’ Investigational mRNA Vaccines for COVID-19

August 02, 2021

From Arcturus Therapeutics Holdings Inc.

Via Business Wire

Arcturus Announces Regulatory Approval to Proceed with Phase 2 Study of ARCT-810 mRNA Therapeutic Candidate for Ornithine Transcarbamylase (OTC) Deficiency

July 28, 2021

From Arcturus Therapeutics Holdings Inc.

Via Business Wire

Arcturus Therapeutics to Report Second Quarter 2021 Financial Results and Provide Corporate Update on August 9, 2021

July 26, 2021

From Arcturus Therapeutics Holdings Inc.

Via Business Wire

Arcturus Therapeutics to Present at Upcoming Investor and Scientific Conferences

July 06, 2021

From Arcturus Therapeutics Holdings Inc.

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For July 2, 2021 ↗

July 02, 2021

Upgrades According to Deutsche Bank, the prior rating for Encompass Health Corp (NYSE:

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

July 02, 2021

Gainers Alector (NASDAQ:ALEC) stock moved upwards by 39.93% to $31.36 during Friday's pre-market session. The market value of their outstanding shares is at $2.5...

Via Benzinga

Return On Capital Employed Overview: Arcturus Therapeutics ↗

June 24, 2021

During Q1, Arcturus Therapeutics's (NASDAQ:ARCT) reported sales totaled $2.13 million. Despite a 85.53% in earnings, the company posted a loss of $57.67 million. In Q4, Arcturus...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For June 21, 2021 ↗

June 21, 2021

Upgrades B of A Securities upgraded the previous rating for Cimarex Energy Co (NYSE:

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

June 21, 2021

Gainers MediciNova (NASDAQ:MNOV) shares moved upwards by 50.79% to $5.67 during Monday's pre-market session. The market value of their outstanding shares is at $276.5...

Via Benzinga

10 Biggest Price Target Changes For Monday ↗

June 21, 2021

SVB Leerink raised Natera, Inc. (NASDAQ:NTRA) pr...

Via Benzinga

Arcturus Therapeutics to Present at Upcoming Investor and Scientific Conferences

June 09, 2021

From Arcturus Therapeutics Holdings Inc.

Via Business Wire

Looking Into Arcturus Therapeutics's Return On Capital Employed ↗

June 08, 2021

In Q1, Arcturus Therapeutics (NASDAQ:ARCT) posted sales of $2.13 million. Earnings were up 85.53%, but Arcturus Therapeutics still reported an overall loss of $57.67 million....

Via Benzinga

High Flyers At Much Lower Altitudes ↗

May 14, 2021

Stocks with extreme valuations have taken a serious haircut since the space peaked on February 22nd.

Via Talk Markets

Arcturus Therapeutics: Q1 Earnings Insights ↗

May 10, 2021

Shares of Arcturus Therapeutics (NASDAQ:ARCT) fell in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share were down 220.90% over...

Via Benzinga

Arcturus Therapeutics Announces First Quarter 2021 Company Overview and Financial Results and Provides New Clinical Data

May 10, 2021

From Arcturus Therapeutics Holdings Inc.

Via Business Wire

The Daily Biotech Pulse: CorMedix Slumps On Delay In Resubmission of DefenCath NDA, Apellis Awaits FDA Decision, Vera Therapeutics Debuts ↗

May 14, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 13) Alexion Pharmaceuticals, Inc...

Via Benzinga

The Daily Biotech Pulse: Minerva, InflaRx Report Positive Data Readouts, Lucira COVID-19 Test Kit Available On Amazon, Decision Day For Heron ↗

May 12, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 11) HOOKIPA Pharma Inc. (NASDAQ...

Via Benzinga

The Daily Biotech Pulse: FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine For Adolescents, Lilly Strikes R&D Collaboration, Vaccine Stocks Novavax, Inovio Sink On Earnings ↗

May 11, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 10) AbbVie Inc. (NYSE: ABBV) -...

Via Benzinga

The Week Ahead In Biotech (May 9-15): Heron, Apellis FDA Decisions, Presentations and Earnings ↗

May 09, 2021

Biotech stocks came under pressure in the week ended May 7 as traders digested a slew of earnings news flow and a handful of clinical trial readouts. COVID-19 vaccine stocks came...

Via Benzinga

The Daily Biotech Pulse: Split Verdict For Chemocentryx, NKarta-CRISPR In Cell Therapy Collaboration, Orphazyme's Clinical Trial Setback, 2 IPOs ↗

May 07, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 6) GT Biopharma, Inc. (NASDAQ:...

Via Benzinga

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Arcturus Therapeutics Holdings Inc (NQ:ARCT)

All News about Arcturus Therapeutics Holdings Inc

Starting at $3.75/week.

Subscribe Today